L-Glutamic acid
|
Basic information |
| Metabolite name | L-Glutamic acid |
 | HMDB0000148 |
 |
C00025 |
 |
33032 |
| Synonyms | glutamic acid; |
| No. of studies | 202 |
|
Basic information |
| Metabolite name | L-Glutamic acid |
| HMDB0000148 |
|
C00025 |
|
33032 |
| Synonyms | glutamic acid; |
| No. of studies | 202 |
|
Relationship between L-Glutamic acid and depression (count: 202) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M010 | Type4 | SSRI-treated responder group vs. non-responder group | Plasma | Human | Down |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M029 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M029 | Type2 | CUMS + BHD group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M053 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M053 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M055 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M064 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Up |
| Study M064 | Type2 | CUMS + fluoxetine group vs. CUMS group | Cecum | Sprague-Dawley rat | Down |
| Study M064 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Cecum | Sprague-Dawley rat | Down |
| Study M065 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M069 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M091 | Type1 | CSDS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Down |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M094 | Type1 | PSD group vs. stroke and control group | Urine | Human | Down |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1020 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1020 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1020 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1032 | Type2 | CUMS + Bupleurum chinense DC and Paeonia lactiflora Pall group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1037 | Type3 | 24h post S-ketamine treatment vs. baseline | Pregenual anterior cingulate cortex | Human | Up |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1039 | Type2 | CUMS + high dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M1039 | Type2 | CUMS + low dose of Angelicae Sinensis Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
| Study M1046 | Type3 | intranasal ketamine group vs. intranasal control group | Medial prefrontal cortex | BALB/cJ mouse | Up |
| Study M1046 | Type3 | intraperitoneal ketamine group vs. intraperitoneal control group | Medial prefrontal cortex | BALB/cJ mouse | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Brain | CD-1 mouse | Down |
| Study M1049 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1058 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Ventral prefrontal white matter | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Dorsal thalamus | Human | Down |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M1066 | Type2 | CUMS + Jianpi group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M1066 | Type2 | CUMS + Shugan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Prefrontal cortex | Cynomolgus monkey | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Down |
| Study M1086 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1094 | Type1 | premenstrual dysphoric disorder liver-qi depression syndrome model group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Up |
| Study M1118 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M1118 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M1126 | Type1 | ovariectomy group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1126 | Type2 | ovariectomy + middle dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1126 | Type2 | ovariectomy + low dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1126 | Type2 | ovariectomy + high dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1129 | Type1 | high dose of perfluorooctane sulfonate group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M1135 | Type2 | PSD + electroacupuncture group vs. PSD group | Faece | Sprague-Dawley rat | Up |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M1141 | Type1 | austere environment group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1143 | Type2 | MDD group, after 12-week escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M144 | Type2 | CUMS + high dose of GSTT group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Up |
| Study M170 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M170 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M177 | Type3 | ketamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | scopolamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | Ro 25-6981 group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M180 | Type1 | dMDD group vs. control group | Plasma | Human | Up |
| Study M182 | Type1 | CUS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M182 | Type2 | CUS + riluzole group vs. CUS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M188 | Type1 | CFSS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M188 | Type1 | CFSS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M194 | Type1 | CFSS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M195 | Type1 | female early life stress group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M205 | Type1 | CUMS group vs. control group | Hippocampus | Mouse | Up |
| Study M205 | Type2 | CUMS + XYS group vs. CUMS group | Hippocampus | Mouse | Down |
| Study M205 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Mouse | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M218 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M242 | Type1 | depression group vs. control group | Occipital cortex | Human | Up |
| Study M244 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M256 | Type4 | rTMS-treated responder group vs. non-responder group at baseline | Dorsolateral prefrontal cortex | Human | Down |
| Study M258 | Type1 | diabetes with depression group vs. diabetes without depression group | Subcortical nuclei | Human | Down |
| Study M277 | Type3 | FST + DMI group vs. FST group | Dorsolateral prefrontal cortex | C57BL/6 mouse | Down |
| Study M285 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M287 | Type1 | chronic depression group vs. control group | Ventromedial prefrontal cortex | Human | Down |
| Study M291 | Type1 | depression group vs. control group | Anterior cingulate | Human | Down |
| Study M292 | Type2 | cLH + ECS group vs. cLH group | Hippocampus | Sprague-Dawley rat | Up |
| Study M292 | Type3 | ECS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M293 | Type1 | depression group vs. control group | Midcingulate cortex | Human | Up |
| Study M293 | Type4 | antidepressant-treated responder group vs. non-responder group | Dorsolateral prefrontal cortex | Human | Up |
| Study M303 | Type1 | depression group vs. control group | Medial prefrontal cortex | Human | Up |
| Study M350 | Type1 | depression group vs. control group | Medial prefrontal cortex | Human | Down |
| Study M359 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M359 | Type2 | ECT-treated depression group post-treatment vs. pre-treatment | Anterior cingulate cortex | Human | Up |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M461 | Type1 | LD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Down |
| Study M481 | Type1 | SD group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M481 | Type2 | SD + ketamine group vs. SD group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M511 | Type1 | Susceptible group vs. control group | Hippocampus | Wistar/ST rat | Up |
| Study M514 | Type3 | ketamine group vs. vehicle group at 14 h | Hippocampus | C57BL/6 mouse | Down |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M519 | Type1 | susceptible group vs. control group | Dorsal hippocampus | C57BL/6N mouse | Up |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M529 | Type1 | depressive symptom group vs. control group | Plasma | Human | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M553 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + low dose of volatile oils group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M559 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + low dose of volatile oils group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M570 | Type1 | CMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M576 | Type1 | MCAO + CUMS group vs. MCAO group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M576 | Type2 | MCAO + CUMS + Ceftriaxone group vs. MCAO + CUMS group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Down |
| Study M591 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Down |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M594 | Type1 | CRS group vs. control group | Entorhinal cortex | C57BL/6 mouse | Up |
| Study M595 | Type1 | CRS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M597 | Type4 | responder group vs. non-responder group, DBS treated MDD at baseline | Rostral anterior cingulate | Human | Down |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M620 | Type1 | MDD group vs. control group | Cerebellum | Human | Up |
| Study M622 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M636 | Type2 | CUMS + Shugan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M644 | Type3 | female tDCS group vs. female sham group | Dorsolateral prefrontal cortex | Human | Down |
| Study M646 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + paroxetine group vs. SMG group | Urine | Sprague-Dawley rat | Down |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M682 | Type1 | fenvalerate-treated male offspring group vs. control male offspring group | Serum | ICR mouse | Up |
| Study M711 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Down |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M719 | Type1 | CUS group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M738 | Type2 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Down |
| Study M759 | Type1 | depression group vs. control group | Ventromedial prefrontal cortex | Human | Down |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Up |
| Study M761 | Type1 | maternal deprivation group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Hippocampus | Swiss albino mouse | Up |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Cortex | Swiss albino mouse | Up |
| Study M764 | Type2 | pentylenetetrazol + middle dose of embelin group vs. pentylenetetrazol group | Cortex | Swiss albino mouse | Down |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Cortex | Swiss albino mouse | Down |
| Study M764 | Type2 | pentylenetetrazol + middle dose of embelin group vs. pentylenetetrazol group | Hippocampus | Swiss albino mouse | Down |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Hippocampus | Swiss albino mouse | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M767 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Up |
| Study M767 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Up |
| Study M767 | Type1 | CUMS group vs. control group | Cortex | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Cortex | C57BL/6 mouse | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M783 | Type1 | stroke + CUMS group vs. stroke group | Faece | Sprague-Dawley rat | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M799 | Type1 | MDD group vs. control group | Middle temporal visual area | Human | Down |
| Study M807 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M814 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M816 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M816 | Type2 | CUMS + middle dose of Baihe Jizihuang Tang group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M849 | Type1 | CUMS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M862 | Type1 | maternal separation adult group vs. control adult group | Medial prefrontal cortex | Wistar rat | Down |
| Study M862 | Type1 | maternal separation adolescent group vs. control adolescent group | Medial prefrontal cortex | Wistar rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Down |
| Study M874 | Type1 | ovariectomy group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M874 | Type2 | ovariectomy + Panax ginseng group vs. ovariectomy group | Urine | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M898 | Type1 | end-stage renal disease with depression group vs. end-stage renal disease without depression group | Serum | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M909 | Type3 | ketamine group vs. control group | Plasma | CD-1 mouse | Down |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M920 | Type1 | anhedonia-susceptible group vs. control grou | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M936 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M940 | Type2 | CUMS + Chaihu group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M942 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Striatum | C57BL/6 mouse | Down |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M962 | Type4 | 24h-post ketamine infusion, remitter vs. non-remitter | Plasma | Human | Down |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Up |
| Study M987 | Type1 | chronic restraint stress group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M988 | Type1 | methionine sulfoximine group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M989 | Type1 | chronic restraint stress group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M989 | Type2 | chronic restraint stress + glutamine diet group vs. chronic restraint stress group | Medial prefrontal cortex | C57BL/6 mouse | Up |